Clarification on SEBI format query for Q2 FY26 results

Regulatory & Legal View source PDF Explain this filing

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹13.80

prior close

₹13.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-0.2% vs market

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.5

15m

+0.0

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-0.7-0.5-0.2

Next day

-2.2-1.0-1.2

-2.9-2.5-0.4

-3.7-3.2-0.5

-4.9-2.2-2.6

-4.5-1.9-2.6

-8.0-3.5-4.5

15d

-14.2-8.8-5.4

-16.4-9.3-7.2

-13.4-4.5-8.9

-1.2+5.4-6.5

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NSE asked Nectar Lifesciences to clarify why its Q2 FY26 (quarter ended Sep 30, 2025) results were not in the SEBI-prescribed format. The company replied that its only wholly-owned subsidiary, NECLIFE PT, is inoperative with no revenue or expenditure, so standalone and consolidated figures are identical. Statutory auditors confirmed the subsidiary is not material to the group.

Likely market impact

Routine procedural clarification with no impact on business, financials, or shareholders.